Long-Term Outcomes in SLE at Peking University People's Hospital
NCT07005479 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2025-06-05
Summary
This study aims to prospectively follow patients diagnosed with Systemic Lupus Erythematosus (SLE) at Peking University People's Hospital, assessing long-term outcomes such as disease activity, organ involvement, survival, and quality of life. Findings will support individualized patient management and contribute to understanding disease progression in the Chinese population.
Conditions
Sponsors & Collaborators
-
Peking University People's Hospital
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-05-21
- Primary Completion
- 2030-05-20
- Completion
- 2032-05-20
Countries
- China
Study Locations
More Related Trials
-
Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis
NCT06167174 ·Status: RECRUITING
-
Efficacy and Safety of Telitacicept in Early SLE
NCT05899907 ·Status: UNKNOWN ·Phase: PHASE4
-
CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus
NCT05930314 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial
NCT04077684 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Belimumab in SLE Patients
NCT04515719 ·Status: COMPLETED ·Phase: PHASE4
-
Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus
NCT00556192 ·Status: COMPLETED ·Phase: PHASE2
-
Low-dose IL-2( Interleukin-2) Treatment in SLE
NCT02084238 ·Status: COMPLETED ·Phase: NA
-
Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
NCT07215754 ·Status: RECRUITING
-
A Prospective Comparative Study Involving Multiple Units to Evaluate the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythematosus.
NCT07069972 ·Status: NOT_YET_RECRUITING
-
Premature Atherosclerosis in Systemic Lupus Erythematosus
NCT04037293 ·Status: UNKNOWN
-
A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus
NCT06900764 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Study of Systemic Lupus Erythematosus
NCT00001372 ·Status: RECRUITING
-
A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321
NCT01305746 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus
NCT05917288 ·Status: COMPLETED ·Phase: PHASE1
-
Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)
NCT05001698 ·Status: COMPLETED ·Phase: PHASE1
-
Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST)
NCT00750971 ·Status: UNKNOWN ·Phase: PHASE2
-
Screening Biomarkers for Severe Lupus Based on Multi-omics Studies
NCT05539001 ·Status: UNKNOWN
-
Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus
NCT02842814 ·Status: COMPLETED ·Phase: NA
-
Rituximab Objective Outcome Measures Trial in SLE
NCT03054259 ·Status: UNKNOWN ·Phase: PHASE2
-
SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis
NCT03164720 ·Status: UNKNOWN
-
A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
NCT05617677 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Scrutinizing the Heterogeneity of SLE: Defining Phenotypes
NCT03348774 ·Status: UNKNOWN
-
A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)
NCT04305197 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Leukocyte Populations in Patients With Chronic Inflammatory
NCT04749875 ·Status: NOT_YET_RECRUITING
-
Serologically Active, Clinically Stable Systemic Lupus Erythematosus
NCT00000421 ·Status: COMPLETED ·Phase: PHASE2